RxDoctor Payments Data
★ My doctorsLook up a doctor →

Andrew Cheng

Internal Medicine · South San Francisco, CANPI 1437659208

Payments from drug & device makers

What this record shows

This record is dominated by other: $55,070,140 of the $55,070,539 with a category attached, or 100.0%. Novo Nordisk AS accounts for 100.0% of it on its own, with 3 other manufacturers making up the rest. Among internal medicine clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$55,070,539in general payments, 2019–2025

Across 5 payments — averaging $11,014,108 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk AS$55.1M
  • Gilead$222
  • Abbott$160
  • Bayer$18

What the payments were for

  • Food & beverage$4000%
  • Other$55,070,140100%

General payments by program year

19
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk AS1$55,070,140
Gilead2$222
Abbott1$160
Bayer1$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$55,070,539 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California →

Other internal medicine in South San Francisco

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →